drugset / Trial / NCT06610643
Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the safety and efficacy of extended remdesivir infusion, targeting on immunocompromised individuals who had positive SARS-CoV-2 PCR despite an oral antiviral agent prescription.
Timeline
- Start
- 2024-09-21
- Primary completion
- 2026-09-30
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nirmatrelvir | Small molecule | — | — |
| Subject | Remdesivir | Small molecule | — | — |
| Subject | Ritonavir | Other / unclassified | — | — |